metformin

Harvard spin-off Cellvie Inc closes $5M seed round

Latest articles

Dyno Therapeutics closes $100m to accelerate gene therapy

Dyno Therapeutics closes $100 million Series A led by Andreessen Horowitz to accelerate AI-powered gene therapy platform. Dyno Therapeutics, Inc, a biotech applying AI to...

Sticking with glutathione could be a smart longevity choice

The body's "master antioxidant" glutathione is a powerful weapon in the fight for longevity, but it diminishes with age; AgelessRx has a range of...

Rise of the retrons – a new gene editing technique

Move over CRISPR... a new gene editing technique enables millions of genetic experiments to be performed simultaneously. Like the best B Movie ever, The Day...

VitaDAO announces “Longevity Molecule” research project

VitaDAO will use advanced machine learning to crunch the data from 1.04 billion prescriptions to understand the impact of drugs on human lifespan. VitaDAO, which...

Most read

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

Spermidine: the mind-enhancing supplement

Scientists are finding that a high intake of dietary spermidine could slow down (or reverse) the brain aging process. Memory loss and slower brain function...
Supplement report

Editor's picks

Dyno Therapeutics closes $100m to accelerate gene therapy

Dyno Therapeutics closes $100 million Series A led by Andreessen Horowitz to accelerate AI-powered gene therapy platform. Dyno Therapeutics, Inc, a biotech applying AI to...

Sticking with glutathione could be a smart longevity choice

The body's "master antioxidant" glutathione is a powerful weapon in the fight for longevity, but it diminishes with age; AgelessRx has a range of...

Rise of the retrons – a new gene editing technique

Move over CRISPR... a new gene editing technique enables millions of genetic experiments to be performed simultaneously. Like the best B Movie ever, The Day...
metformin

Kizoo leads $5M seed round at Harvard spin-off Cellvie in pursuit of new treatment modality: Therapeutic Mitochondria Transfer (TMT).

Harvard spin-off Cellvie Inc has closed its $5M seed round led by Kizoo Technology Capital to advance its product pipeline, including a first application in rejuvenation.

Longevity.Technology: Mitochondria are intimately tied to the origin of complex life, the energy of the young and the decline of the old. As powerhouses of the cell, they generate most of the cellular energy and operate as critical intra-cellular communication nodes. Mitochondria dysfunction has been tied to myriad diseases, including neurodegenerative ailments such as Parkinson’s and Alzheimer’s, heart attacks and strokes, and age-related degeneration.

Cellvie was founded in the US in 2018 by Drs James McCully, Alexander Schueller, Pedro del Nido and Sitaram Emani and is headquartered close to Zürich, Switzerland. Dr McCully pioneered the approach of mitochondria augmentation and replacement at Harvard Medical School and the team has now set out to leverage the therapeutic potential of mitochondria for a new treatment modality in ischemia-reperfusion injury, aging and beyond.

Mitochondria play a crucial role in the aging process, activating factors and metabolic pathways involved in longevity. Their dysfunction impacts on both lifespan and healthspan.

“But treating mitochondria has proven to be an arduous challenge,” said McCully, who is also Associate Professor of Surgery at Boston’s Children’s Hospital and Harvard Medical School. “That is why we turned to introducing healthy, viable mitochondria into cells where these organelles are impaired. To great effect. We can sustainably reinvigorate cells’ failing energy metabolism.”

The potential of TMT was recently demonstrated in a clinical investigation at Boston Children’s Hospital; paediatric patients on heart-lung-support after suffering a cardiogenic shock received the treatment to revitalise their heart muscle. 80% of these children experienced myocardial recovery, which compares with an expected 29%, as reported in a publication forthcoming in The Journal of Thoracic and Cardiovascular Surgery.

“The implications of our findings are groundbreaking. We may have the chance to bring about a new treatment modality,” said Dr Alexander Schueller, founder and CEO of Cellvie. “The investment will enable us to pursue the platform broadly, including a first application in aging, where the need for mitochondria-recovery is particularly dear.”

 


 

“We believe it is time to approach the problem from a different angle … we are hopeful to make a difference in this field.”

 


 


To date, Cellvie has focused primarily on ischemia-reperfusion injury (IRI), which manifests itself whenever the blood flow to a part of the body is interrupted and subsequently reintroduced. Well-known medical conditions causing IRI include heart attacks, strokes and organ transplantation. Cellvie is also pursuing an indication in organ transplantation, for which the FDA awarded orphan drug designation in 2020. The capital injection will be employed for preparing for market, expanding Cellvie’s product pipeline and to prepare an IND submission for a clinical study in kidney transplantation.

Longevity.Technology spoke to Dr Schueller to find out the impetus for TMT. “After the many failed attempts to drug mitochondria, we believe it is time to approach the problem from a different angle,” he told us. “Therapeutic mitochondria transfer was shown to reinvigorate the cell energy metabolism by means of mitochondria augmentation and replacement. With loss of mitochondria function or mass recurrent themes in aging-related degeneration, we are hopeful to make a difference in this field.”

Kizoo is part of the Forever Healthy Group and supports the creation of start-ups turning research on the root causes of aging into therapies and services for human application. Investments include Cellvie, Underdog, Revel Pharmaceuticals, Elevian, Oisin Biotechnologies, LIfT BioSiences, MAIA Biotechnology, FoxBio and Turn.bio.

“We were immediately attracted to the potential of Cellvie’s approach to emerge as a novel category of medicines,” said Frank Schueler, Managing Director at Kizoo Technology Capital. “With mitochondria dysfunction a common denominator to disease and aging alike, Cellvie’s ability to affect the cell energy metabolism may pave the road to address hitherto intractable human ailments”. Frank Schueler will join the company’s Board of Directors.

Is Therapeutic Mitochondria Transfer set to be the next big category in rejuvenation? R42 Group’s new AI and Longevity Fund participated in a $250,000 pre-seed round for Mitrix Bio‘s whole-body mitochondrial transfusion research – also joined by the Longevity Tech Fund. Read our exclusive interview with Mitrix’s CEO Tom Benson here.

Image courtesy of Cellvie

Comment on this article

Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.
metformin

Most popular

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

Spermidine: the mind-enhancing supplement

Scientists are finding that a high intake of dietary spermidine could slow down (or reverse) the brain aging process. Memory loss and slower brain function...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...
Supplement report

Related articles

Dyno Therapeutics closes $100m to accelerate gene therapy

Dyno Therapeutics closes $100 million Series A led by Andreessen Horowitz to accelerate AI-powered gene therapy platform. Dyno Therapeutics, Inc, a biotech applying AI to...

VitaDAO announces “Longevity Molecule” research project

VitaDAO will use advanced machine learning to crunch the data from 1.04 billion prescriptions to understand the impact of drugs on human lifespan. VitaDAO, which...

Harnessing the immune system to target cellular senescence

Deciduous Therapeutics aims for clinical trials of immune-activating senotherapeutic by 2023, with metabolic disease and fibrosis among potential indications. Californian start-up Deciduous Therapeutics has emerged...

Building a longevity biotech from scratch

Alchemab exec talks company creation and how antibody therapeutics may play a role in longevity biotech. Last week, we covered Alchemab Therapeutics’ $82 million Series...

Cellino: longevity powered by AI, stem cells & democracy

From a serendipitous meeting of minds to laser-enabled precision, Cellino is leveraging AI and pluripotent stem cells for longevity. We speak to CEO and...
Supps report ad middle